Medicines Formulary

Medicines A–Z

A

Drug name	NICE TAs	Comments
Abatacept	TA195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed	Hospital use only
Abciximab injection	TA47 - Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (partially updated by CG94)	Hospital use only
Abemaciclib (Verzenios®)	TA563 - Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy TA810: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Abidec drops (25ml)		Contains arachis (peanut) oil.
Abiraterone tablets	TA259 - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen TA387 - Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Acalabrutinib	TA689 - Acalabrutinib for treating chronic lymphocytic leukaemia
Acamprosate E/C tablets
Acenocoumarol tablets
Acetazolamide		Intercranial hypertension (unlicensed indication)
Acetazolamide 500mg injection

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.